Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study

摘要

IntroductionLiraglutide and sitagliptin were compared on glycemic control and all-cause healthcare costs over a 1-year period among older adults with type 2 diabetes (65–89?years) enrolled in a national Medicare Advantage Prescription Drug health plan.MethodsThis was a retrospective study in which the index date was the first prescription fill for liraglutide or sitagliptin between 25 January 2010 and 31 December 2014. Post-index treatment persistence and glycosylated hemoglobin (HbA1 c ) at baseline and 1?year (±?90?days) post-index date were required. Patients were excluded if their record included use of insulin during the baseline period. Inverse probability of treatment weighting using stabilized weights was employed with final covariate adjusted regression modeling to estimate the primary outcome (mean change in HbA1 c ) and secondary outcomes (achieving glycemic goal and costs), each at 1-year post-index date.ResultsOverall, 3056 patients met the selection criteria, of whom 218 filled prescriptions for liraglutide and 2838 for sitagliptin. Adjusted mean change in HbA1 c at 1?year post-index was???0.42 with liraglutide versus ??0.12 with sitagliptin ( P =?0.0012). Adjusted odds of achieving the treatment goals of HbA1 c ??7% and achieving an HbA1 c reduction of?≥?1% were higher for those on liraglutide than for those on sitagliptin (1.68, 95% confidence interval [CI] 1.25–2.24 and 1.76, 95% CI 1.31–2.36), respectively. Total healthcare costs in those achieving an HbA1 c of ?7% were not significantly different between treatment groups but were higher within the liraglutide group for those achieving an HbA1 c ??8%.ConclusionsWhen compared to sitagliptin, liraglutide was associated with greater achievement of an HbA1 c ??7% over a 1-year period in an older population. This finding was not associated with a statistically significant increase in all-cause total healthcare costs, although costs were slightly higher in the liraglutide group than in the sitagliptin group.